SLXN Silexion Therapeutics: קפיטליזציה חשבונאית

This price chart on the GURU.Markets platform illustrates the price action of Silexion Therapeutics Corp (SLXN), where the current figure stands at 0.00. Company management is focused on validating the efficacy of its oncology platforms while awaiting market recognition of test results. The business relies on the LODER gene delivery system, which creates a closed patent cycle. Silexion Therapeutics Corp is also developing methods to suppress KRAS mutations in pancreatic cancer.

Book value capitalization determines the real value of a company's assets minus all debt obligations, capturing the fundamental basis of the company's value at the current moment. By analyzing the capital amount in the balance sheet of Silexion Therapeutics Corp (SLXN), an investor assesses the financial cushion for the development of RNA cancer drugs, where the final profitability of patents will depend on the successful completion of regulatory reviews.